Western Research Park

Sernova Announces U.S. Phase I/II Cell Pouch Clinical Trial with Prominent Diabetes Clinical Investigator

Leading Surgeon and Researcher in Islet Transplantation at the University of Chicago to act as
Clinical Trial Principal Investigator. Study to focus on severely diabetic patients with
hypoglycemia unawareness

LONDON, Ontario, May 08, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF)
(FSE:PSH), announces Dr. Piotr Witkowski, M.D., Ph.D., a leading expert in type 1 diabetes (T1D) and islet transplantation,  as the Clinical Trial Principal Investigator for Sernova’s new clinical study. Dr Witkowski, at the University of Chicago site, will work closely with Sernova’s team to conduct the clinical and
regulatory aspects of the Cell Pouch trial.

Dr. Witkowski is a widely published diabetes researcher and respected surgeon with a longstanding
record of success in both basic science and clinical research pertaining to islet cell and
abdominal organ transplantation. Among other accomplishments, he was instrumental in developing an
optimized islet isolation technique that greatly improved success in clinical transplants. Under
Dr. Witkowski's leadership, multidisciplinary research teams at the University of Chicago are
currently conducting several studies designed to improve the quality and outcomes of islet cell
transplantation in patients with T1D.

“Sernova’s achievement to commence US human clinical trials is a key step to improving the
therapeutic treatment for people living with diabetes. This Cell Pouch safety and efficacy trial
aims to reduce the risk of hypoglycemia unawareness, a complication in which a patient is unable to
recognize and control impending hypoglycemia resulting in a drop in blood sugar that can have life
threatening consequences,” said Dr. Witkowski. “Our experienced diabetes treatment team at the
University of Chicago sees the potential of this transformative therapy to benefit and
substantially improve the care of T1D.”

“Improving the quality of life and outcomes of people with diabetes are Sernova’s main priorities,
and we are grateful to have the opportunity to work with Dr. Witkowski and his expert team at the
University of Chicago, a team known for outstanding diabetes research and patient care,” stated Dr.
Philip Toleikis, Sernova’s President & CEO.

The study is a Phase I/II, non-randomized, unblinded, single-arm, company sponsored trial. Under
the clinical leadership of Dr. Witkowski, University of Chicago Medicine, patients with
hypoglycemia unawareness will be enrolled in the study under informed consent. Patients then will
be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue
development in the Cell Pouch, an initial dose of purified islets under strict release criteria
will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for
approximately six months. At this point a decision will be made with regards to the transplant of a
second islet dose with subsequent safety and efficacy follow up. Patients will then be further
followed for one year, with interim patient results released at periodic intervals consistent with
an open label study.

About Dr. Witkowski
Piotr Witkowski M.D. Ph.D. is an Associate Professor of Surgery and a transplant surgeon at the
University of Chicago Medicine. He has been involved in islet transplantation research for the
past 17 years, initially at Columbia University in New York City and then as a Director of the
Pancreatic Islet Transplantation Program at the University of Chicago Medicine. For the last nine
years, Dr. Witkowski has been conducting multiple clinical studies in intraportal islet
allotransplantation in patients with brittle type diabetes as well as islet autotransplantation in
patients with chronic pancreatitis. Recently, he accomplished a phase 3 clinical trial and is
currently preparing application to the FDA for islet graft as a biological product, which is
pivotal to enable islet transplantation to become available to patients as a standard of care
procedure. Being aware of shortcomings of intrahepatic islet transplantation, Dr Witkowski has
been working on optimization of the subcutaneous location for improved islet engraftment. He has
proven the concept that this pre-vascularized site enhances islet survival in a preclinical
diabetes model.

About Sernova Corp
Sernova Corp is developing disruptive regenerative medical technologies using a medical device
(Cell Pouch) and immune protected therapeutic cells to improve the treatment and quality of life of
people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders
including hemophilia, and other diseases treated through replacement of proteins or hormones
missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:
Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939; philip.toleikis@sernova.com
www.sernova.com